CASE REPORT {#omz016s1}
===========

A 32-year-old man with stage IVA T2N2M0 squamous cell cancer of the tonsil (p16 positive) was initially treated with induction Docetaxel Carboplatin and 5FU followed by carboplatin and XRT to 70 Gy achieved a complete response in August 2015. In January 2017, he had a metastatic recurrence with a 1.7 × 1.3 cm right upper lobe lesion and 2.3 × 1.4 cm right paratracheal lesion. PD-L1 IHC showed high (90%) expression. The patient received pembrolizumab between February 2017 and February 2018 achieving an early complete response within 2 months of his treatment with no eventful grade three toxicities except for immune-mediated hypothyroidism which was managed with levothyroxine. His medical history was negative for any skin disorders or skin cancers.

Five months after stopping his treatment he noticed two solitary hypopigmented vitiliginous patches (Fig. [1](#omz016F1){ref-type="fig"}) and a small cluster of hyperpigmented lesions (Fig. [2](#omz016F2){ref-type="fig"}) one on his left preauricular area and the other on the right angle of his mouth. No preceding erythema was noted. The lesions were non-pruritic. His most recent imaging in July 2018 continues to show no evidence of disease. A skin punch biopsy of the hypopigmented lesions was sent for pathological analysis (Figs [3](#omz016F3){ref-type="fig"}--[5](#omz016F5){ref-type="fig"}). Morphological description of (hematoxylin--eosin) HE findings showed mild epidermal acanthosis, parakeratosis, and some interface dermatitis with few dyskeratotic cells and underlying lymphocytic infiltrate with scattered dermal melanophages. Immunohistochemical (IHC) Fontana stain, negative SOX10 stain identifies no argentaffin granules and melanin or melanoma making this consistent with a vitiligo lesion morphologically appearing to be immunotherapy related.

![Clinical photograph of the angle of the mouth with hypopigmented patch.](omz016f01){#omz016F1}

![Clinical photograph of hyperpigmented macules preceding hypopigmentation lower extremity with hypopigmented lesions.](omz016f02){#omz016F2}

![Skin biopsy (hematoxylin--eosin stain, original magnification ×20). Mild epidermal acanthosis, focal parakeratosis and interface dermatitis lymphocytic infiltrate with scattered dermal melanophages.](omz016f03){#omz016F3}

![IHC Fontana stain identifies no argentaffin granules and melanin.](omz016f04){#omz016F4}

![Negative SOX10 stain (melanoma marker).](omz016f05){#omz016F5}

DISCUSSION {#omz016s2}
==========

Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events \[[@omz016C1]\]. Vitiligoid irAE (immune-related adverse event) in a non-melanoma solid cancer has not been commonly described in literature when treated with pembrolizumab.

The development of vitiligo represents a well-recognized adverse event in patients with melanoma treated with anti-CTLA-4 and anti-programmed death (PD-1)/programmed death ligand (PD-L1) antibodies. Depigmentation may result from induction of antimelanoma immunity through a cytotoxic T-cell-mediated response with a cross-reaction against different epitopes or antigens expressed by both melanoma cells and normal melanocytes (e.g. MART-1, GP100, TRP1-2, tyrosinase) \[[@omz016C2], [@omz016C3]\].

The overall incidence of newly developed vitiligo with PD-1 inhibitors varies between 8 and 25% \[[@omz016C2]\]. The relative risk of all-grade vitiligo with anti-PD-1 and anti-CTLA-4 (meta-analysis) is 16.3% \[[@omz016C4]\]. Vitiligoid lesions, however, occur more frequently with anti-PD-1 agents than with other immunotherapies (overall incidence of 3.4%) previously used in melanoma, including anti-CTLA-4 \[[@omz016C5]\].

Vitiligo has not been described to date in other types of solid cancers treated with PD-1/PD-L1 antibodies \[[@omz016C6]\], but a potential underestimation because of a lack of systematic examination of the entire skin surface cannot be ruled out.

Vitiligo usually develops after several months of treatment and does not appear to be dose related \[[@omz016C7]\]. It can be preceded by erythematous inflammatory lesions and may appear to look like Pityriasis rosea \[[@omz016C2]\]. Lesions are mainly generalized and bilateral, but focal or segmental presentations can also be seen as vitiligoid lesions localized around skin metastases \[[@omz016C7]\]. Associated hair repigmentation or depigmentation can be also observed \[[@omz016C8]\].

In pooled analysis, patients who presented with vitiligo during immunotherapy were found to have a higher frequency and severity of irAEs than those without vitiligo \[[@omz016C2], [@omz016C9]\]. Although vitiligo can precede the radiologic objective responses, the occurrence of vitiligo cannot be considered an early sign of response to immunotherapy. This perhaps could be an important indicator of antimelanoma immunity and associated improved survival. Whether this relates to solid cancers as well we are not sure \[[@omz016C3]\]. It has been hypothesized that PD-1 inhibitors induce vitiligo-like depigmentation in melanoma patients via the antimelanoma immune response, which may also target healthy melanocytes owing to overlapping antigen expression \[[@omz016C10]\].

PD-1 inhibitors are associated with a variety of cutaneous irAEs, including pruritus, maculopapular eruptions, eczema, lichenoid dermatoses, psoriasiform eruptions, vitiligo, sarcoidosis and severe reactions such as Stevens--Johnson syndrome/toxic epidermal necrolysis \[[@omz016C9]\].

The pathogenesis perhaps involves an aberrant targeting of antigens into the dermis/epidermis by reactivated CD4^+^/CD8^+^ T cells, generate an inflammatory process after cross-reaction with normal skin. However, the specific self-antigens driving T-cell infiltration into the skin have not been identified \[[@omz016C7]\]. Vitiligo can be observed in other tumor types beyond melanoma when receiving immunotherapy and may be a sign of potent immune activation.
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